✦ LIBER ✦

Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease

✍ Scribed by X. Antón Alvarez; Andrés Franco; Lucía Fernández-Novoa; Ramón Cacabelos

Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 959 KB
Volume: 29
Category: Article
ISSN: 1044-7393
DOI: 10.1007/bf02815005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of serum IL-1β, sIL-2R, IL-6,

Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis

✍ A. Bal; E. Unlu; G. Bahar; E. Aydog; E. Eksioglu; R. Yorgancioglu 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 91 KB

Higher cytotoxic activity and increased

Higher cytotoxic activity and increased levels of IL-1β, IL-6, and TNF-α in patients undergoing cardiopulmonary bypass

✍ Francesc Martí; Joan Muñoz; Matilde Peiró; Esther Bertran; Carme Ferrán; Carmen 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Increased levels of tumor necrosis facto

Increased levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) in tracheal aspirates of newborns with pneumonia

✍ C. Buck; H. Gallati; F. Pohlandt; P. Bartmann 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 639 KB

Serum Levels of IL-lβ, IL-6, TNF-α, sTNF

Serum Levels of IL-lβ, IL-6, TNF-α, sTNF-RI and CRP in Patients with oral cavity cancer

✍ Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska 📂 Article 📅 1997 🏛 Springer Netherlands 🌐 English ⚖ 324 KB

A multinational, randomised, 12-week stu

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB